AIBILI has been recognised as an EATRIS Expert Centre covering areas as regulatory strategy and execution and health technology assessment.
EATRIS put out a call for an expression of interest from institutions to provide EATRIS decentralised expert services. Seven applied and were ratified by the EATRIS Boards. The Centres cover a wide range of areas, such as innovation management, regulatory strategy and execution, and health technology assessment.
AIBILI 2022 report is now available!
Please check it here.
Proud to have Patrícia Barreto from AIBILI AMD Research Group receiving the Plácido Prize by the Sociedade Portuguesa de Oftalmologia, during the 65th Portuguese Congress of Ophthalmology.
The work entitled “Genetics and the Mediterranean diet: What is the risk for Age-Related Macular Degeneration” was developed by Patrícia Barreto. The assessment of each individual’s genetic risk may be relevant to assess the benefit of personalized non-pharmacological strategies, namely modifiable risk factors for the prevention of Age-Related Macular Disease.
Co-workers: Patrícia Barreto, Cláudia Farinha, Rita Coimbra, Maria Luz Cachulo, Joana Barbosa de Melo, Carel Hoyng, Yara Lechanteur, José Cunha-Vaz and Rufino Silva.
To celebrate the 30 years of INFARMED and for the first time in Portugal the National Pharmacovigilance Day, INFARMED organises on 13/12/2022 a session in Lisbon.
AIBILI is one of the Regional Pharmacovigilance Units and its Coordinator, Dr. Lisete Lemos will have a talk dedicated to the challenges and opportunities for the Regional Units.
For more information please check here.
Nesta edição do boletim “FARMACOVIGILÂNCIA: Atualizações de segurança de medicamentos” informa-se acerca de novas recomendações no tratamento da síndrome hepatorrenal com medicamentos que contêm terlipressina, recomendações sobre medidas de minimização do risco de reações adversas graves para os medicamentos da classe de inibidores das JAK utilizados em doenças inflamatórias, bem como informação sobre a revisão do perfil de segurança do Topamax® (topiramato) no seguimento de um estudo que revelou risco aumentado de deficiências no neurodesenvolvimento em crianças com exposição pré-natal, e ainda um alerta sobre o uso de vacinas vivas em lactentes cujas mães receberam ustecinumab durante a gravidez. Destacam-se ainda atualizações de segurança sobre as vacinas e medicamentos aprovados para a COVID-19. Por último, é apresentada a atividade científica da Unidade de Farmacovigilância de Coimbra (UFC) e os resultados da sua atividade no terceiro trimestre de 2022.
Consulte: Farmacovigilância – Atualizações de segurança de medicamentos, Vol. 9, n.º 1
Diabetes is a health condition that can affect many parts of the body, including the eyes. Routine eye exams can help identify the early stages of eye problems and protect a person’s vision.
Do not miss AIBILI’s speakers at the roundtables on Personalised Medicine (Inês Pereira Marques) and Big Data/Artificial Intelligence (Luis Mendes).
This Friday, September 16th during the Technology Exhibition dedicated to Health Innovation organised by the Coimbra University and AIBILI.
More information here: https://www.uc.pt/ucbusiness/inovacao-em-saude/
AIBILI has been recognized as a Technology and Innovation Center.
The Technology and Innovation Centers (CTI) are entities dedicated to the production, dissemination and transmission of knowledge, oriented to companies and the creation of economic value, contributing, to the pursuit of public policy objectives, framed in the areas of national priority expertise or regions in which they operate.
ANI was responsible for this process that falls under the Recovery and Resilience Program (PRR).
More information: https://files.dre.pt/2s/2022/08/152000002/0000200003.pdf
The Honorary President of AIBILI, Prof. José Cunha-Vaz, was distinguished today, June 9th, in Berlin, Germany, with the Arnall Patz Medal. The Arnall Patz Medal is intended to distinguish outstanding contributions to the study of Retinal Vascular Diseases. The ceremony took place during the 45th Congress of the Macula Society.
This distinction is recognition of the scientific career and clinical research activity of José Cunha-Vaz, evident in his innovative contributions, which over the years have greatly contributed to the knowledge and treatment of retinal diseases, and more particularly diabetic retinopathy, a leading cause of blindness.
AIBILI is happy to participate in the Azores Health Summit which will take place on 12-13/05/2022. Our President, Prof. Conceição Lobo, will share AIBILI’s experience in the development and implementation of diabetic retinopathy screening programmes using artificial intelligence. This participation will be complemented by João Diogo Ramos from our partnering company Retmarker SA.
